Cargando…

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma

Detalles Bibliográficos
Autores principales: Talreja, Vikas T., Noronha, Vanita, Joshi, Amit, Patil, Vijay, Mahajan, Abhishek, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699239/
https://www.ncbi.nlm.nih.gov/pubmed/31489287
http://dx.doi.org/10.4103/sajc.sajc_18_19
_version_ 1783444680999960576
author Talreja, Vikas T.
Noronha, Vanita
Joshi, Amit
Patil, Vijay
Mahajan, Abhishek
Prabhash, Kumar
author_facet Talreja, Vikas T.
Noronha, Vanita
Joshi, Amit
Patil, Vijay
Mahajan, Abhishek
Prabhash, Kumar
author_sort Talreja, Vikas T.
collection PubMed
description
format Online
Article
Text
id pubmed-6699239
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-66992392019-09-05 An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma Talreja, Vikas T. Noronha, Vanita Joshi, Amit Patil, Vijay Mahajan, Abhishek Prabhash, Kumar South Asian J Cancer Letter to the Editor Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6699239/ /pubmed/31489287 http://dx.doi.org/10.4103/sajc.sajc_18_19 Text en Copyright: © 2019 The South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Letter to the Editor
Talreja, Vikas T.
Noronha, Vanita
Joshi, Amit
Patil, Vijay
Mahajan, Abhishek
Prabhash, Kumar
An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
title An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
title_full An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
title_fullStr An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
title_full_unstemmed An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
title_short An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
title_sort exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699239/
https://www.ncbi.nlm.nih.gov/pubmed/31489287
http://dx.doi.org/10.4103/sajc.sajc_18_19
work_keys_str_mv AT talrejavikast anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma
AT noronhavanita anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma
AT joshiamit anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma
AT patilvijay anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma
AT mahajanabhishek anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma
AT prabhashkumar anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma
AT talrejavikast exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma
AT noronhavanita exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma
AT joshiamit exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma
AT patilvijay exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma
AT mahajanabhishek exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma
AT prabhashkumar exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma